We used the established AMPK activator, 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) (500 μM), the Akt inhibitor, wortmannin (1 μM), and the mTOR inhibitor, rapamycin (200 nM) and examined and compared their effects to the effects of CA treatment. The gene discussed is AKT1; the disease is cancer.